, Seung Bae Yoon
Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
© 2026 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
The authors have no potential conflicts of interest.
Funding
None.
Author Contributions
Conceptualization: SBY; Data curation: all authors; Formal analysis: all authors; Supervision: SBY; Writing–original draft: all authors; Writing–review & editing: SBY.
| Study | Year | No. patients | Needle type | Needle size | Specimens | No. of analyzed genes | Sequencing success (%) | KRAS detection (%) | Actionable gene detection (%) |
|---|---|---|---|---|---|---|---|---|---|
| Valero et al.18 | 2016 | 19 | FNA | NR | Fresh frozen | 143 | 89.5 | 82.4 | 17.6 |
| Dreyer et al.19 | 2019 | 41 | FNB | 22 | FFPE tissue | 409 | 100 | 96.2 | 34.6 |
| Carrara et al.20 | 2021 | 33 | FNB | 22, 25 | Fresh frozen | 50 | 97.0 | 93.8 | NR |
| Habib et al.21 | 2021 | 59 | FNA | 19 | Fresh frozen | 124 | NR | 85.7 | NR |
| Semaan et al.22 | 2021 | 23 | FNA | 22, 25 | Fresh smear | 60 | 100 | 82.6 | 21.7 |
| Hisada et al.12 | 2022 | 33 | FNB | 19, 22, 25 | FFPE tissue | 50 | 63.6 | 100 | 33.3 |
| Yokoyama et al.23 | 2022 | 31 | FNB | 19, 22 | Liquid-based cytology | NR | 100 | 80.0 | NR |
| Redegalli et al.17 | 2023 | 76 | FNA, FNB | 22 | Alcohol-fixed smear | 47 | 88.2 | 87.3 | 15.0 |
| Kamata et al.24 | 2023 | 50 | FNB | 19 | Fresh frozen | 409 | 93.6 | 84.0 | NR |
| Study | Year | No. patients | Needle type | Needle size | Specimens | No. of analyzed genes | Sequencing success (%) | KRAS detection (%) | Actionable gene detection (%) |
|---|---|---|---|---|---|---|---|---|---|
| Valero et al.18 | 2016 | 19 | FNA | NR | Fresh frozen | 143 | 89.5 | 82.4 | 17.6 |
| Dreyer et al.19 | 2019 | 41 | FNB | 22 | FFPE tissue | 409 | 100 | 96.2 | 34.6 |
| Carrara et al.20 | 2021 | 33 | FNB | 22, 25 | Fresh frozen | 50 | 97.0 | 93.8 | NR |
| Habib et al.21 | 2021 | 59 | FNA | 19 | Fresh frozen | 124 | NR | 85.7 | NR |
| Semaan et al.22 | 2021 | 23 | FNA | 22, 25 | Fresh smear | 60 | 100 | 82.6 | 21.7 |
| Hisada et al.12 | 2022 | 33 | FNB | 19, 22, 25 | FFPE tissue | 50 | 63.6 | 100 | 33.3 |
| Yokoyama et al.23 | 2022 | 31 | FNB | 19, 22 | Liquid-based cytology | NR | 100 | 80.0 | NR |
| Redegalli et al.17 | 2023 | 76 | FNA, FNB | 22 | Alcohol-fixed smear | 47 | 88.2 | 87.3 | 15.0 |
| Kamata et al.24 | 2023 | 50 | FNB | 19 | Fresh frozen | 409 | 93.6 | 84.0 | NR |
| Category | Factors | Impact on NGS yield | Key notes for endoscopists |
|---|---|---|---|
| Needle type | FNA vs. FNB | Mixed evidence; no clear superiority | FNB may provide larger cores and higher DNA in some studies; FNA may yield higher cellularity; overall difference not statistically significant. |
| Needle gauge | 19-G/22-G/25-G | Larger needles may increase tissue volume and DNA yield | 22-G or larger is preferred when technically feasible; 19-G may be limited by stiffness and maneuverability, especially in pancreatic head. |
| No. of passes | 2 vs. 3 | 2 vs. 3 passes showed no difference | Two dedicated passes with 22-G Franseen-tip needle are sufficient for CGP; additional passes offer no added benefit. |
| Specimen format | Cytology vs. histology | No major difference in pooled sequencing success (>80%) | Both formats acceptable; histology may help architecture-based analyses, cytology often has higher tumor cellularity. |
| Processing method | FFPE, fresh-frozen, liquid-based | No major difference in pooled sequencing success (>80%) | Choose method based on institutional workflow; avoid delays or suboptimal fixation. |
| Platform requirements | DNA input thresholds | Major determinant of sequencing success | Some platforms require >200 ng DNA (e.g., OncoGuide), while others can operate with ≥10 ng; choose platform compatible with expected tissue yield. |
| Category | Genomic finding | Prevalence (%) | Clinical implications |
|---|---|---|---|
| Major driver mutations | KRAS | 86 | Core driver of PDAC; essential for molecular profiling |
| TP53 | 63 | Tumor suppressor loss; adverse biology | |
| SMAD4 | 22 | Associated with metastatic patterns | |
| CDKN2A | 18 | Cell-cycle dysregulation | |
| Actionable mutations | HRR pathway (BRCA1/2, PALB2, ATM) | 10–12 | Sensitivity to platinum agents or PARP inhibitors |
| BRAF V600E | ~3 | Targetable with BRAF-directed therapy | |
| KRAS G12C | ~2 | Targetable with KRAS G12C inhibitors | |
| Immunotherapy biomarkers | High TMB (≥10 Mut/Mb) | 1–2 | Potential ICI response (rare in PDAC) |
| MSI-H | <1 | Strong predictor of ICI benefit (rare in PDAC) | |
| KRAS mutation subtypes | G12D, G12V, G12R | G12R: associated with better outcomes & slower metastatic progression (emerging evidence) | |
| Clonal metrics | High KRAS VAF | May reflect high tumor purity; associated with worse outcomes and chemo-resistance (emerging evidence) |
EUS, endoscopic ultrasound; NGS, next-generation sequencing; PDAC, pancreatic ductal adenocarcinoma; FNA, fine-needle aspiration; FNB, fine-needle biopsy; FFPE, formalin-fixed paraffin-embedded; NR, not-reported.
NGS, next-generation sequencing; EUS, endoscopic ultrasound; FNA, fine-needle aspiration; FNB, fine-needle biopsy; G, gauge; CGP, comprehensive genomic profiling; FFPE, formalin-fixed paraffin-embedded.
PDAC, pancreatic ductal adenocarcinoma; HRR, homologous recombination repair; TMB, tumor mutational burden; MSI-H, microsatellite instability-high; ICI, immune checkpoint inhibitor; VAF, variant allele frequency.
